US20170044218A1 - Use of a HIV derived accessory protein for the reactivation of latent HIV - Google Patents

Use of a HIV derived accessory protein for the reactivation of latent HIV Download PDF

Info

Publication number
US20170044218A1
US20170044218A1 US15/306,218 US201515306218A US2017044218A1 US 20170044218 A1 US20170044218 A1 US 20170044218A1 US 201515306218 A US201515306218 A US 201515306218A US 2017044218 A1 US2017044218 A1 US 2017044218A1
Authority
US
United States
Prior art keywords
hiv
protein
tat
amino acid
latent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/306,218
Inventor
Daniel Boden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Infectious Diseases Diagnostics BVBA
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Assigned to JANSSEN INFECTIOUS DISEASES - DIAGNOSTICS BVBA reassignment JANSSEN INFECTIOUS DISEASES - DIAGNOSTICS BVBA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BODEN, Daniel
Assigned to JANSSEN R&D IRELAND reassignment JANSSEN R&D IRELAND ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JANSSEN INFECTIOUS DISEASES - DIAGNOSTICS BVBA
Assigned to JANSSEN SCIENCES IRELAND UC reassignment JANSSEN SCIENCES IRELAND UC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JANSSEN R&D IRELAND
Publication of US20170044218A1 publication Critical patent/US20170044218A1/en
Assigned to Janssen Sciences Ireland Unlimited Company reassignment Janssen Sciences Ireland Unlimited Company CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: JANSSEN SCIENCES IRELAND UC
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells in an HIV-infected individual.
  • a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells in an HIV-infected individual.
  • HIV-derived accessory protein tat trans-activator of transcription
  • HIV latent human immunodeficiency virus
  • HAART Highly active antiretroviral therapy
  • HAART can suppress HIV-1 levels in plasma to below the limit of detection of clinical assays ( ⁇ 50 copies/ml) and reduce the morbidity and mortality of HIV-1 infection.
  • HAART alone fails to cure HIV infection.
  • HAART leaves latent integrated proviruses unaffected.
  • Latent viral genomes reside in a small pool of infected resting memory CD4+ T-cells that constitute a stable viral reservoir. In these cells, the provirus remains transcriptionally silent as long as the host cells are in a quiescent state. This allows the virus to evade host immune surveillance and rebound quickly following discontinuation of HAART.
  • the remarkable stability of the latent viral reservoir necessitates lifelong HAART. Given the potential for toxicity and resistance, elimination of the latent reservoir has been proposed as a goal worthy of a major scientific effort.
  • Therapies targeting the latent reservoir generally involve reactivation of latent virus.
  • Expression of viral genes renders infected cells susceptible to viral cytopathic effects and immune clearance.
  • this reactivation strategy could ultimately purge latent virus from infected individuals.
  • latent viruses respond to T-cell activation signals initial attempts to deplete the latent reservoir through T-cell reception (TCR) stimulation using anti-CD3 antibodies proved toxic. The toxicity likely resulted from global T-cell activation with subsequent release of pro-inflammatory cytokines. Therefore, an ideal treatment should reactivate latent HIV-1, but avoid overall T-cell activation.
  • the current invention aims to using a mutant of the HIV-derived accessory protein tat (trans-activator of transcription) for the reactivation and subsequent eradication of latent HIV.
  • the full length tat protein [86-101 aa] is translated from two different exons where exon-1 [1-72 aa] contains all domains essential for trans-activation. Mutagenesis experiments surprisingly identified the first 57 N-terminal amino acids of wild type tat as minimal reactivation domain (Table 2).
  • the 66 amino acid deletion mutant [T66] with a reactivation capacity close to full length exon 1 Tat72 (Table 2) potently activates HIV in latently infected cell lines (Table 3) and primary CD4 cells (Table 4).
  • Tat derivatives were evaluated ex vivo on patient-derived latently infected CD4 cells and compared with the most potent reference compounds known to reactivate latent HIV in vitro and ex vivo.
  • Tat 66 protein induced HIV activation and exceeded by far the reactivation achieved by reference compounds such as PHA (Phytohaemagglutinin), PMA (Phorbol myristate acetate), and SAHA (suberoyl anilide hydroxamic acid).
  • PHA Physicalhaemagglutinin
  • PMA Phorbol myristate acetate
  • SAHA suberoyl anilide hydroxamic acid
  • the current invention thus relates to the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.
  • HIV latent human immunodeficiency virus
  • the invention concerns a method of reactivating latent HIV present in a host cell by exposing a HIV infected cell with a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof.
  • Tat stands for, as mentioned above, “Trans-Activator of Transcription” and Tat consists of between 86 and 101 amino acids depending on the subtype.
  • tat is a protein which is encoded for by the tat gene in HIV-1.
  • Tat is a regulatory protein that drastically enhances the efficiency of viral transcription.
  • said protein comprises at least a wild-type HIV-derived accessory protein tat for the reactivation of latent HIV but more preferably said protein comprises at least the first 57 N-terminal amino acids of wild-type tat (86-101 aa) for the reactivation of latent HIV.
  • Said protein may also comprise at least the first 60 N-terminal amino acids of wild-type tat (86-101 aa) for the reactivation of latent HIV.
  • Said 57 amino acids are represented by the following SEQ ID No. 1: MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFMTKALGISYGRKKRR QRRR.
  • the mentioned 60 amino acids are represented by the following SEQ ID No; 2: MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFMTKALGISYGRKKRR QRRRAHQ
  • the 66 amino acid deletion mutant [T66] according to the invention with a reactivation capacity close to full length exon 1 Tat72 has the amino acid sequence of SEQ ID NO 3:
  • amino acid is meant, for purposes of the specification and claims and in reference to the protein according to the present invention, to refer to a molecule that has at least one free amine group and at least one free carboxyl group and may further comprise one or more free chemical reactive group other than an amine or a carboxyl group (e.g., a hydroxyl, a sulfhydryl, etc).
  • the amino acid may be a naturally occurring amino acid (e.g., L-amino acid and is depicted in this specification as a capital letter in the sequence), a non-naturally occurring amino acid (e.g., D-amino acid and is depicted in this specification as a small letter in the sequence), a synthetic amino acid, a modified amino acid, an amino acid derivative, an amino acid precursor, and a conservative substitution.
  • a naturally occurring amino acid e.g., L-amino acid and is depicted in this specification as a capital letter in the sequence
  • a non-naturally occurring amino acid e.g., D-amino acid and is depicted in this specification as a small letter in the sequence
  • synthetic amino acid e.g., a synthetic amino acid, a modified amino acid, an amino acid derivative, an amino acid precursor, and a conservative substitution.
  • amino acids incorporated into a protein will depend, in part, on the specific physical, chemical or biological characteristics required of the protein. Such characteristics are determined, in part, by determination of helicity and activity.
  • amino acids in a synthetic protein may be comprised of one or more of naturally occurring (L-) amino acid and non-naturally occurring (D-) amino acid.
  • a “conservative substitution” is used in this specification to mean one or more amino acids substitution in the sequence of the protein such that the protein still demonstrate the unexpected, improved biological activity. This includes substitutions of amino acids having substantially the same charge, size, hydrophilicity, and/or aromaticity as the amino acid replaced.
  • transactivation domains of host transcription factors such as NFkB or NFAT.
  • TAD transactivation domains
  • Table 5 shows the increased activity of T66 linked to TADs from NFkB p65 and NFAT2.
  • Another option would be to add a cell-targeting moiety to HIV tat such as anti-CD3 antibody or IL7 to target the transactivator more specifically to cells that are known to harbor latent HIV.
  • the T66 protein is used in a concentration of 1 ⁇ M to 10 ⁇ M, preferably of 2 ⁇ M to 5 ⁇ M.
  • HIV can be eradicated by addition of an antiviral agent such as a small molecule and/or antibody directed towards HIV in order to realize a cure of HIV.
  • an antiviral agent such as a small molecule and/or antibody directed towards HIV in order to realize a cure of HIV.
  • Part of the invention is also a pharmaceutical composition
  • a pharmaceutical composition comprising the protein above referenced and a pharmaceutically accepted carrier.
  • To the present invention also belongs a method for treating a subject with human immunodeficiency virus (HIV) comprising the steps of:
  • Tat variant % Tat72 activity 1-66 92.2 ( ⁇ 12.7) 1-64 77.2 ( ⁇ 10.8) 1-60 77.2 ( ⁇ 10.8) 1-57 40.2 ( ⁇ 2.3) 1-50 0.0 (NA)
  • Activity is expressed in % with respect to the activity achieved by full length Tat72 exon-1 set to 100%. Shown data are mean values [n ⁇ 4] with indicated (standard deviation).
  • Tat-mediated transactivation was determined by triple plasmid transfection of HEK293 cells with pEF-T, a Tat expression plasmid, LTR-FLuc, a HIV LTR-controlled firefly luciferase reporter plasmid and pEF1-RLuc, a EF1 ⁇ promoter driven Renilla luciferase reporter plasmid. Luciferase reporter activities were assessed 24 h post transfection using the Dual-Glo luciferase assay [Promega]. The measured HIV LTR luciferase data were normalized by Renilla luciferase data retrieved from the pEF1-RLuc plasmid. LTR activity is expressed as percentage of wild type exon-1 Tat72 activity.
  • MT4-LTR-GFP cells were incubated overnight with different Tat variants at the indicated concentration [ ⁇ g/ml]. LTR activation was determined by flow cytometry.
  • CD4 + T cells were isolated from 200 ml whole blood using CD4 microbeads (Miltenyi Biotec) according to manufacturer's protocol. Blood originates from HIV-infected individuals under long-term HAART with undetectable plasma virus. Ten to twenty replicates of cell pools plated at 1 ⁇ 10 6 CD4 + T cells/well were incubated overnight with compounds or mock controls (DMSO/PBS). Total RNA was isolated from each replicate using the Magmax 96 Total RNA isolation kit (Ambion) following the manufacturer's protocol. Duplicate cDNA reactions were performed on each RNA replicate using SuperScript III First-Strand Synthesis kit (Invitrogen) according to the manufacturer's protocol.
  • Quantitative real-time PCR was conducted on each cDNA applying gag-specific primers and the nucleic acid detection dye Sybr Green I [Invitrogen]. Standard curves were generated using cDNA synthesized from in vitro transcribed RNA. The detection limit of the QPCR assay was determined to be within 1-10 copies/reaction. Cycle threshold (ct) value ⁇ 40 were excluded from the analysis. The Wilcoxon rank sum test was used to calculate the statistical significance of the relative HIV-1 gag RNA copy number between different conditions.
  • T66 fusion proteins result in increased activation when compared to T66.

Abstract

The present invention concerns the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.

Description

  • The present invention relates to the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells in an HIV-infected individual.
  • Highly active antiretroviral therapy (HAART) can suppress HIV-1 levels in plasma to below the limit of detection of clinical assays (<50 copies/ml) and reduce the morbidity and mortality of HIV-1 infection. However, HAART alone fails to cure HIV infection. In particular, HAART leaves latent integrated proviruses unaffected. Latent viral genomes reside in a small pool of infected resting memory CD4+ T-cells that constitute a stable viral reservoir. In these cells, the provirus remains transcriptionally silent as long as the host cells are in a quiescent state. This allows the virus to evade host immune surveillance and rebound quickly following discontinuation of HAART. The remarkable stability of the latent viral reservoir necessitates lifelong HAART. Given the potential for toxicity and resistance, elimination of the latent reservoir has been proposed as a goal worthy of a major scientific effort.
  • Therapies targeting the latent reservoir generally involve reactivation of latent virus. Expression of viral genes renders infected cells susceptible to viral cytopathic effects and immune clearance. Along with HAART, this reactivation strategy could ultimately purge latent virus from infected individuals. While latent viruses respond to T-cell activation signals initial attempts to deplete the latent reservoir through T-cell reception (TCR) stimulation using anti-CD3 antibodies proved toxic. The toxicity likely resulted from global T-cell activation with subsequent release of pro-inflammatory cytokines. Therefore, an ideal treatment should reactivate latent HIV-1, but avoid overall T-cell activation.
  • However, despite global extensive research efforts, there still exists a high unmet medical need for reliable, safe and convenient compounds able to reactivate latent HIV from above mentioned reservoir in HIV-infected patients.
  • The current invention aims to using a mutant of the HIV-derived accessory protein tat (trans-activator of transcription) for the reactivation and subsequent eradication of latent HIV. The full length tat protein [86-101 aa] is translated from two different exons where exon-1 [1-72 aa] contains all domains essential for trans-activation. Mutagenesis experiments surprisingly identified the first 57 N-terminal amino acids of wild type tat as minimal reactivation domain (Table 2). The 66 amino acid deletion mutant [T66] with a reactivation capacity close to full length exon 1 Tat72 (Table 2) potently activates HIV in latently infected cell lines (Table 3) and primary CD4 cells (Table 4). The activity of Tat derivatives was evaluated ex vivo on patient-derived latently infected CD4 cells and compared with the most potent reference compounds known to reactivate latent HIV in vitro and ex vivo. Unexpectedly Tat 66 protein induced HIV activation and exceeded by far the reactivation achieved by reference compounds such as PHA (Phytohaemagglutinin), PMA (Phorbol myristate acetate), and SAHA (suberoyl anilide hydroxamic acid). The inclusion of a tat-derived protein in a treatment regimen will be essential to cure HIV infected people.
  • The current invention thus relates to the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.
  • Alternatively it can be expressed that the invention concerns a method of reactivating latent HIV present in a host cell by exposing a HIV infected cell with a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof.
  • Tat stands for, as mentioned above, “Trans-Activator of Transcription” and Tat consists of between 86 and 101 amino acids depending on the subtype.
  • Also, in molecular biology, tat is a protein which is encoded for by the tat gene in HIV-1. Tat is a regulatory protein that drastically enhances the efficiency of viral transcription.
  • Preferably said protein comprises at least a wild-type HIV-derived accessory protein tat for the reactivation of latent HIV but more preferably said protein comprises at least the first 57 N-terminal amino acids of wild-type tat (86-101 aa) for the reactivation of latent HIV.
  • Said protein may also comprise at least the first 60 N-terminal amino acids of wild-type tat (86-101 aa) for the reactivation of latent HIV.
  • Said 57 amino acids are represented by the following SEQ ID No. 1: MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFMTKALGISYGRKKRR QRRR.
  • The mentioned 60 amino acids are represented by the following SEQ ID No; 2: MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFMTKALGISYGRKKRR QRRRAHQ
  • The 66 amino acid deletion mutant [T66] according to the invention with a reactivation capacity close to full length exon 1 Tat72 has the amino acid sequence of SEQ ID NO 3:
  • MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFMTKALGISYGRK
    KRRQRRRAHQNSQTHQ.
  • In Table 1 below substitutions are provided for each position in these SEQ ID NO: 1, 2 and 3 respectively which are feasible in order to obtain a protein falling within the scope of the present invention.
  • TABLE 1
    Primary T66 amino acid sequence with indicated
    substitutions
    No T66 Substitutions
     1. M
     2. E D
     3. P L
     4. V I
     5. D N
     6. P H
     7. R N/S/K
     8. L I
     9. E D
    10. P
    11. W
    12. K N/E/Q/H
    13. H Q/R
    14. P S
    15. G
    16. S
    17. Q R/K
    18. P
    19. K R/T/A/I/S/Q/N/E/G/P
    20. T
    21. A P/D/N/E/S
    22. C
    23. T N/S
    24. N K/P/T/S/A/Q/R/G
    25. C
    26. Y F
    27. C
    28. K
    29. K R/H/A/M/V/Q/E/S/I/Y
    30. C
    31. C S
    32. F Y/W/L/M
    33. H
    34. C
    35. Q L/P/Y/I/V/M/A/T
    36. V L/W/A/I/S/Y/M/D/K/H/N/R/T/F/C
    37. C
    38. F L
    39. M T/Q/I/L/H/V/A/S
    40. T K/N/H/Q/S/R/A/T/D
    41. K
    42. A G
    43. L
    44. G S/R
    45. I T/V/L
    46. S F/Y/V/I/C/P/L/H/R
    47. Y H/N
    48. G
    49. R K
    50. K R
    51. K R
    52. R W/Q
    53. R K/S/G/T/Q/N
    54. Q H/R/P/L/K/S
    55. R Q/H
    56. R H/P/Q/T/S
    57. R G/S/T/N/K/A/P/Q
    58. A T/P/S
    59. H P/S/A/T
    60. Q P/H/R/E/K/N/Y/L
    61. N S/D/G/R/C/A/H
    62. S N/G/Y/R/D/C/H
    63. Q K/E/G/P/S/T/A/R
    64. T D/A/I/N/S/P/G/V/H/E/L
    65. H N/D/Y/R
    66. Q K
    • DEFINITIONS
  • By the term “amino acid” is meant, for purposes of the specification and claims and in reference to the protein according to the present invention, to refer to a molecule that has at least one free amine group and at least one free carboxyl group and may further comprise one or more free chemical reactive group other than an amine or a carboxyl group (e.g., a hydroxyl, a sulfhydryl, etc). The amino acid may be a naturally occurring amino acid (e.g., L-amino acid and is depicted in this specification as a capital letter in the sequence), a non-naturally occurring amino acid (e.g., D-amino acid and is depicted in this specification as a small letter in the sequence), a synthetic amino acid, a modified amino acid, an amino acid derivative, an amino acid precursor, and a conservative substitution.
  • A person skilled in the art would know that the choice of amino acids incorporated into a protein will depend, in part, on the specific physical, chemical or biological characteristics required of the protein. Such characteristics are determined, in part, by determination of helicity and activity. For example, a skilled person would know that amino acids in a synthetic protein may be comprised of one or more of naturally occurring (L-) amino acid and non-naturally occurring (D-) amino acid.
  • A “conservative substitution” is used in this specification to mean one or more amino acids substitution in the sequence of the protein such that the protein still demonstrate the unexpected, improved biological activity. This includes substitutions of amino acids having substantially the same charge, size, hydrophilicity, and/or aromaticity as the amino acid replaced.
  • Nomenclature Used in this Specification
  • For the L-natural amino acids, as known in the art, the following abbreviations were used:
  • Symbol
    Name 3-Letter 1-Letter
    Alanine Ala A
    Arginine Arg R
    Asparagine Asn N
    Aspartic acid Asp D
    Cysteine Cys C
    Glutamic Acid Glu E
    Glutamine Gln Q
    Glycine Gly G
    Histidine His H
    Isoleucine Ile I
    Leucine Leu L
    Lysine Lys K
    Methionine Met M
    Phenylalanine Phe F
    Proline Pro P
    Serine Ser S
    Threonine Thr T
    Tryptophan Trp W
    Tyrosine Tyr Y
    Valine Val V
  • Furthermore part of the invention is the use of any of the above mentioned proteins wherein said protein comprises in addition another protein forming a fusion protein. Examples of such domains fused to HIV tat are transactivation domains (TAD) of host transcription factors such as NFkB or NFAT. By using the specific recruitment of Tat to the HIV LTR, additional transactivation domains are delivered in close proximity to the HIV promoter and surprisingly result in additional activation. Table 5 shows the increased activity of T66 linked to TADs from NFkB p65 and NFAT2. Another option would be to add a cell-targeting moiety to HIV tat such as anti-CD3 antibody or IL7 to target the transactivator more specifically to cells that are known to harbor latent HIV.
  • The T66 protein is used in a concentration of 1 μM to 10 μM, preferably of 2 μM to 5 μM.
  • After the use of the protein according to the invention HIV can be eradicated by addition of an antiviral agent such as a small molecule and/or antibody directed towards HIV in order to realize a cure of HIV.
  • Part of the invention is also a pharmaceutical composition comprising the protein above referenced and a pharmaceutically accepted carrier.
  • To the present invention also belongs a method for treating a subject with human immunodeficiency virus (HIV) comprising the steps of:
      • a) administering to said subject an effective amount of the pharmaceutical composition comprising the protein according to the invention and a pharmaceutically accepted carrier; and
      • b) administering to said subject an effective amount of one or more anti-viral agent.
    Experimental Part
  • TABLE 2
    HIV LTR transactivation by Tat C-terminal deletion mutants.
    Tat variant % Tat72 activity
    1-66 92.2 (±12.7)
    1-64 77.2 (±10.8)
    1-60 77.2 (±10.8)
    1-57 40.2 (±2.3) 
    1-50 0.0 (NA) 
  • Activity is expressed in % with respect to the activity achieved by full length Tat72 exon-1 set to 100%. Shown data are mean values [n≧4] with indicated (standard deviation).
  • Tat-mediated transactivation was determined by triple plasmid transfection of HEK293 cells with pEF-T, a Tat expression plasmid, LTR-FLuc, a HIV LTR-controlled firefly luciferase reporter plasmid and pEF1-RLuc, a EF1α promoter driven Renilla luciferase reporter plasmid. Luciferase reporter activities were assessed 24 h post transfection using the Dual-Glo luciferase assay [Promega]. The measured HIV LTR luciferase data were normalized by Renilla luciferase data retrieved from the pEF1-RLuc plasmid. LTR activity is expressed as percentage of wild type exon-1 Tat72 activity.
  • TABLE 3
    Titration of tat protein variants on latent
    HIV LTR-GFP reporter cell line.
    Tat [μg] 100 80 70 60 50 40 30 0
    T72 93.7 93.8 88.8 76.3 60.4 47.2 18.6 1.2
    T66 94.5 93.9 87.6 88.7 87.0 53.8 45.7 1.0
    T60 93.3 95.8 95.2 92.1 87.0 33.4 28.5 1.1
  • MT4-LTR-GFP cells were incubated overnight with different Tat variants at the indicated concentration [μg/ml]. LTR activation was determined by flow cytometry.
  • TABLE 4
    Ex vivo activation of CD4 cells with
    Tat protein T60, T66, and T86.
    % Activity (PMA/PHA)
    Tat Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
    T60 405/328 ND 213/196 ND ND/254
    T66 838/680 1121/986 530/487 ND/479 ND/636
    T86 ND ND ND ND/436 ND/408
  • Activation of latent HIV from primary CD4+ T cells by overnight incubation with different Tat proteins. Indicated numbers represent HIV activation in percentage to reference compounds PMA and PHA set to 100%. The shown % increase compared to PMA/PHA is statistically significant (p<0.01).
  • CD4+ T cells were isolated from 200 ml whole blood using CD4 microbeads (Miltenyi Biotec) according to manufacturer's protocol. Blood originates from HIV-infected individuals under long-term HAART with undetectable plasma virus. Ten to twenty replicates of cell pools plated at 1×106 CD4+ T cells/well were incubated overnight with compounds or mock controls (DMSO/PBS). Total RNA was isolated from each replicate using the Magmax 96 Total RNA isolation kit (Ambion) following the manufacturer's protocol. Duplicate cDNA reactions were performed on each RNA replicate using SuperScript III First-Strand Synthesis kit (Invitrogen) according to the manufacturer's protocol. Quantitative real-time PCR (QPCR) was conducted on each cDNA applying gag-specific primers and the nucleic acid detection dye Sybr Green I [Invitrogen]. Standard curves were generated using cDNA synthesized from in vitro transcribed RNA. The detection limit of the QPCR assay was determined to be within 1-10 copies/reaction. Cycle threshold (ct) value≧40 were excluded from the analysis. The Wilcoxon rank sum test was used to calculate the statistical significance of the relative HIV-1 gag RNA copy number between different conditions.
  • TABLE 5
    T66 fusion proteins result in increased
    activation when compared to T66.
    pEF-T ID FLUC RLUC FLUCnorm Fold % T66
    T66 15437 267 37049 26 100
    T66-NFK114 25480 380 42918 30 116
    T66-NFAT2C 22614 304 47674 33 129
    Cell control 1450 641 1448 1 4
  • Triple plasmid transfection of HEK293 cells with pEF-T (Tat expression plasmid), LTR-FLuc (HIV LTR-controlled firefly luciferase reporter plasmid) and pEF1-RLuc (EF1α promoter driven Renilla luciferase reporter plasmid). Luciferase reporter activities were assessed 24 h post transfection using the Dual-Glo luciferase assay [Promega]. The measured HIV LTR luciferase data were normalized by Renilla luciferase data collected from the co-transfected pEF1-RLuc signal. LTR activation is either expressed as fold increase over cell control or as percentage of T66 activity.

Claims (13)

1.-9. (canceled)
10. An isolated protein having the amino acid sequence of the group consisting of: SEQ ID. NO: 1, SEQ ID. NO: 2 and SEQ ID. NO: 3.
11. An isolated protein of claim 10, wherein the protein has the amino acid sequence of SEQ ID. NO: 1.
12. An isolated protein of claim 10, wherein the protein has the amino acid sequence of SEQ ID. NO: 2.
13. An isolated protein of claim 10, wherein the protein has the amino acid sequence of SEQ ID. NO: 3.
14. A pharmaceutical composition, comprising the protein of claim 10.
15. A pharmaceutical composition of claim 10, wherein the protein has the amino acid sequence of SEQ ID. NO: 1.
16. A pharmaceutical composition of claim 10, wherein the protein has the amino acid sequence of SEQ ID. NO: 2.
17. A pharmaceutical composition of claim 10, wherein the protein has the amino acid sequence of SEQ ID. NO: 3.
18. A method for treating a subject with human immunodeficiency virus (HIV) comprising the steps of:
a) administering to said subject an effective amount of the composition of claim 14; and
b) administering to said subject an effective amount of one or more anti-viral agent.
19. A method of treating a subject of claim 18, wherein the subject is administered an effective amount of the composition of claim 15.
20. A method of treating a subject of claim 18, wherein the subject is administered an effective amount of the composition of claim 16.
21. A method of treating a subject of claim 18, wherein the subject is administered an effective amount of the composition of claim 17.
US15/306,218 2014-04-24 2015-04-23 Use of a HIV derived accessory protein for the reactivation of latent HIV Abandoned US20170044218A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14165811.2 2014-04-24
EP14165811 2014-04-24
PCT/EP2015/058747 WO2015162192A1 (en) 2014-04-24 2015-04-23 Use of a hiv derived accessory protein for the reactivation of latent hiv

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/058747 A-371-Of-International WO2015162192A1 (en) 2014-04-24 2015-04-23 Use of a hiv derived accessory protein for the reactivation of latent hiv

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/460,872 Division US11098085B2 (en) 2014-04-24 2019-07-02 Use of a HIV derived accessory protein for the reactivation of latent HIV

Publications (1)

Publication Number Publication Date
US20170044218A1 true US20170044218A1 (en) 2017-02-16

Family

ID=50679847

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/306,218 Abandoned US20170044218A1 (en) 2014-04-24 2015-04-23 Use of a HIV derived accessory protein for the reactivation of latent HIV
US16/460,872 Active US11098085B2 (en) 2014-04-24 2019-07-02 Use of a HIV derived accessory protein for the reactivation of latent HIV

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/460,872 Active US11098085B2 (en) 2014-04-24 2019-07-02 Use of a HIV derived accessory protein for the reactivation of latent HIV

Country Status (4)

Country Link
US (2) US20170044218A1 (en)
EP (1) EP3134107B1 (en)
ES (1) ES2804750T3 (en)
WO (1) WO2015162192A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218420A1 (en) * 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969584B2 (en) * 1997-06-12 2005-11-29 Rigel Pharmaceuticals, Inc. Combinatorial enzymatic complexes
US6589763B1 (en) 1998-11-26 2003-07-08 Heinrich-Pette-Institute Retroviral hybrid vectors pseudotyped with LCMV
US20010008627A1 (en) * 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
KR100465589B1 (en) 2001-04-20 2005-01-13 허만욱 Anti-obesity polypeptides
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
US7244814B2 (en) * 2002-02-21 2007-07-17 University Of Medicine & Dentistry Of New Jersey Variant Tat proteins and methods for use thereof
WO2004056391A1 (en) 2002-12-20 2004-07-08 The University Of New South Wales A method of immunisation and agents useful for same
DE102004034461B4 (en) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gene Therapy of Solid Tumors by Retroviral Arenavirus Glycoprotein-Pseudotyped Vectors
US8247613B2 (en) * 2006-04-17 2012-08-21 The J. David Gladstone Institutes Methods and compositions for the synergistic activation of latent HIV
EP2485759A4 (en) * 2009-10-09 2013-07-24 Univ New York Methods, agents and peptides for inducing an innate immune response in hiv vaccination
GB201004656D0 (en) * 2010-03-19 2010-05-05 Ensoli Barbara Immune therapy
AU2011255621A1 (en) * 2010-05-18 2012-12-20 The Uab Research Foundation Latent Human Immunodeficiency Virus reactivation
WO2012018856A2 (en) * 2010-08-02 2012-02-09 Virxsys Corporation Hiv vaccine therapy with concomitant antiviral monotherapy

Also Published As

Publication number Publication date
US20190337992A1 (en) 2019-11-07
ES2804750T3 (en) 2021-02-09
EP3134107A1 (en) 2017-03-01
WO2015162192A1 (en) 2015-10-29
US11098085B2 (en) 2021-08-24
EP3134107B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
Chong et al. A lipopeptide HIV-1/2 fusion inhibitor with highly potent in vitro, ex vivo, and in vivo antiviral activity
McMillan et al. HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR
US8034899B2 (en) HIV fusion inhibitor peptides with improved biological properties
Fletcher et al. Inhibition of retroviral replication by members of the TRIM protein family
Lu et al. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket-or membrane-binding domain
WO2023155318A1 (en) Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof
ES2286818T3 (en) FUNCTION AND ACTIVITY OF VPR.
US11098085B2 (en) Use of a HIV derived accessory protein for the reactivation of latent HIV
AU2017410525B2 (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
US5874225A (en) Identification of compounds that modulate HIV-1 vpr protein activity
WO2009095500A1 (en) Inhibitors of lentiviral replication
RU2290197C2 (en) Pharmaceutical agent for treatment of hiv-infection, composition containing thereof and methods for its using
AU2007328228B2 (en) Peptide and treatment for HIV-1 infection
US20210000895A1 (en) Exosome targeting of cd4+ expressing cells
Ueno et al. Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide
US20160030518A1 (en) Compositions and methods for inhibiting viral activity
WO2018141089A1 (en) Hiv inhibiting broad-spectrum lipopeptide, derivatives thereof, pharmaceutical compositions thereof, and use thereof
Yu et al. Therapeutic efficacy and resistance selection of a lipopeptide fusion inhibitor in simian immunodeficiency virus-infected rhesus macaques
US20230302123A1 (en) Replication-deficient adenovirus
US20050221288A1 (en) Variant tat proteins and methods for use thereof
US20160310567A1 (en) Compositions for inhibiting viral replication and methods of use and production thereof
Harakidas Development of systems for the isolation of cellular cofactors involved in HIV-1 rev function
Danappa Jayappa Molecular analysis of the contributions of human immunodeficiency virus type-1 integrase in post entry steps of early stage virus replication
Chen et al. Characterisation of novel anti-HIV/tuberculosis natural product analogues
Guo Understanding the multiple roles of the CA-SP1 boundary region in HIV-1 Gag multimerization, gag-membrane binding and viral RNA packaging

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN SCIENCES IRELAND UC, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN R&D IRELAND;REEL/FRAME:040108/0660

Effective date: 20141229

Owner name: JANSSEN INFECTIOUS DISEASES - DIAGNOSTICS BVBA, BE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BODEN, DANIEL;REEL/FRAME:040108/0517

Effective date: 20140424

Owner name: JANSSEN R&D IRELAND, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JANSSEN INFECTIOUS DISEASES - DIAGNOSTICS BVBA;REEL/FRAME:040108/0574

Effective date: 20140424

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

AS Assignment

Owner name: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY, IRELAN

Free format text: CHANGE OF NAME;ASSIGNOR:JANSSEN SCIENCES IRELAND UC;REEL/FRAME:049688/0201

Effective date: 20181008

Owner name: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY, IRELAND

Free format text: CHANGE OF NAME;ASSIGNOR:JANSSEN SCIENCES IRELAND UC;REEL/FRAME:049688/0201

Effective date: 20181008

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION